New combo therapy targets hard-to-treat liver metastases in colorectal cancer
NCT ID NCT06356584
First seen May 02, 2026 · Last updated May 23, 2026 · Updated 4 times
Summary
This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific cancer subtype (MSS/pMMR) will be randomly assigned to receive the drug combo with or without radiotherapy. The goal is to see if the triple therapy improves how long the cancer stays under control and overall survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jinbo Yue
RECRUITINGJinan, Shandong, 250000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.